ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2426

Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2452

Multimodal Ultrasound in the Assessment of Sarcopenia-related Muscle Involvement in Patients with Systemic Sclerosis: A Multicentric Study

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1853

Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 2199

Mycobacterial Infection and Renal and Bladder Malignancy in 2 IFNopathy Patients on High Doses of JAK Inhibitors

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2404

Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2446

Nailfold Videocapillaroscopy Findings in Patients with Limited Cutaneous versus Diffuse Cutaneous Systemic Sclerosis: The First Detailed Retrospective Study

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2320

Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2312

National Prevalence of Psoriatic Arthritis in the United States: Data from National Health and Nutrition Examination Survey [NHANES]

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2038

Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2399

Nationwide Analysis of Endovascular Thrombectomy in Ischemic Stroke Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mortality and Healthcare Utilization

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1872

Nationwide Analysis of Prosthetic Joint Complications with and Without Inflammatory Arthritis

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: L10

Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

(L01–L14) Late-Breaking Posters

10:30AM-12:30PM: Abstract Number: 2406

Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1780

Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1941

No Show QI at Hoxworth Rheumatology Clinic: Evaluating the Impact of Live Telephone Calls Combined with Automated Reminders

Health Services Research – ACR/ARP Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].